Table 1.
References | Citation | Species | Cerebral artery | Critical observations |
---|---|---|---|---|
Yagi et al., 2015 | (87) | Mouse | Olfactory | SAH augments myogenic reactivity and reduces CBF. Etanercept (TNF inhibitor) and JTE-013 (S1P2 receptor antagonist) normalize myogenic reactivity and reduce neurological injury in SAH; etanercept improves CBF in SAH. |
Lidington et al., 2019 | (93) | Mouse | Olfactory | SAH augments myogenic reactivity and reduces CBF. Lumacaftor (CFTR corrector therapeutic) normalizes myogenic reactivity, improves CBF and reduces neurological injury in SAH. |
Deng et al., 2018 | (94) | Mouse | Middle Cerebral | Hemolyzed blood reversibly augments myogenic tone in vitro and in vivo. Superoxide scavenging (Tempol) prevents myogenic tone augmentation in vitro and in vivo. |
Nystoriak et al., 2011 | (95) | Rat | Parenchymal | SAH augments pressure-dependent membrane depolarization, calcium influx and vasoconstriction. |
Wellman and Koide, 2013 | (96) | Rat | Parenchymal | SAH augments potassium currents and myogenic tone. |
Gong et al., 2019 | (97) | Rat | Middle Cerebral | SAH increases TRMP4 expression/activity, resulting in augmented depolarization and vascular tone. Blockade of TRMP4 (9-phenanthrol) significantly improves vascular tone and CBF in SAH. |
Harder et al., 1987 | (98) | Dog | Basilar | SAH reduces basilar artery potassium conductance and induces basilar artery vasospasm. Inhibiting potassium efflux (nicorandil) reduces basilar artery constriction in vitro and in vivo. |
Ishiguro et al., 2002 | (99) | Rabbit | Basilar, Posterior and Cerebellar | SAH augments posterior and cerebellar artery myogenic tone. SAH augments basilar artery constriction in vivo (measured angiographically). |
Koide et al., 2011 | (100) | Rabbit | Posterior and Cerebellar | SAH augments arterial wall depolarization, calcium influx and myogenic tone. SAH reduces calcium spark frequency, suggesting reduced BK channel activity. |
A blood injection model of SAH was used in all publications. BK, calcium activated large conductance potassium channels; CBF, cerebral blood flow; S1P2, Sphingosine-1-phosphate receptor 2; SAH, Subarachnoid hemorrhage; TRMP4, Transient receptor potential melastatin-4.